Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Romiplostim biosimilar by Qilu Pharmaceutical for Thrombocytopenia: Likelihood of Approval
Romiplostim biosimilar is under clinical development by Qilu Pharmaceutical and currently in Phase III for Thrombocytopenia. According to GlobalData, Phase...